Safety and tolerability of a novel oral formulation of amphotericin B: Phase I EnACT Trial.

Conclusions. Oral cAMB was well tolerated when given in 4-6 divided daily doses without the toxicities commonly seen with IV AMB.
PMID: 32747357 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - August 2, 2020 Category: Microbiology Authors: Skipper C, Atukunda M, Stadelman A, Engen N, Bangdiwala A, Huppler Hullsiek K, Abassi M, Rhein J, Nicol MR, Laker E, Williams DA, Mannino R, Matkovits T, Meya DB, Boulware DR Tags: Antimicrob Agents Chemother Source Type: research